Recap: Eagle Pharmaceuticals Q1 Earnings

 

Shares of Eagle Pharmaceuticals EGRX remained unaffected after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 71.43% year over year to $0.24, which missed the estimate of $0.65.

Revenue of $41,249,000 decreased by 10.37% from the same period last year, which missed the estimate of $45,410,000.

Guidance

Eagle Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 10, 2021

Time: 08:30 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.eagleus.com%2F&eventid=3082041&sessionid=1&key=83C4DA2F2901A058D02F2E2C5BD59ABC&regTag=&V2=false&sourcepage=register

Price Action

Company's 52-week high was at $56.16

Company's 52-week low was at $36.48

Price action over last quarter: Up 3.30%

Company Profile

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!